AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data

Benzinga Newsdesk www.benzinga.com Neutral 54.9%

Neg 0% Neu 54.9% Pos 0%

Submission supported by data from Phase 3 pivotal AFFIRM study
If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction

Comments

No comments yet. Be the first!